Key Takeaways:
Biotechnology company Dannuo Pharmaceutical launched its Hong Kong initial public offering, seeking to raise approximately HKD 558 million for research and development.
The offering has attracted five cornerstone investors, including AMR Action Fund and Orient Asset Management, who subscribed for a total of approximately USD 29.8 million in shares, according to the prospectus.
Dannuo is offering 8.2806 million H shares at HKD 75.7 per share. The public offering runs from May 14 to May 19, with trading expected to commence on May 22 under the ticker 06872.HK.
The IPO proceeds are critical for advancing Dannuo's pipeline, with 71% earmarked for its core products targeting infections like Helicobacter pylori. Long-term investor WUXI APPTEC will retain a 5.5% stake, showing continued confidence.
Beyond its core products, the company plans to allocate 7.2% of the proceeds to build a manufacturing facility in Zhongshan, Guangdong Province, and another 7.3% to the R&D of other pipeline candidates. A further 7.5% is designated for working capital.
Dannuo Pharmaceutical specializes in developing treatments for bacterial infections and related diseases. Its lead candidate, Rifotnizole (TNP-2198), is being developed for H. pylori infection, while Riforoquinone (TNP-2092) targets complex implant-related bacterial infections.
The offering prices the company against other pre-revenue biotech firms on the Hong Kong exchange. The first day of trading on May 22 will be a key test of investor appetite for biotechnology assets in the current market.
This article is for informational purposes only and does not constitute investment advice.
